• FH1: Designing Better iHep Maturation Assays

  2026-10-01

  FH1 small molecule supports more functional iPS-derived hepatocyte-like cells through coordinated albumin, AFP, CYP3A4, and morphology readouts. This article presents an assay-design framework that connects hepatocyte maturation with emerging light-controlled gene regulation while clearly separating established evidence from future applications.

• (-)-Blebbistatin in Mechanogenomic Force Assays

  2026-10-01

  (-)-Blebbistatin is a selective non-muscle myosin II inhibitor for dissecting how actomyosin tension controls chromatin and gene expression. This guide translates force-mode mechanobiology into practical assay design, controls, and interpretation.

• Clarithromycin CYP3A Inhibitor Workflows

  2026-09-30

  Build reproducible CYP3A inhibition assays with Clarithromycin for statin metabolism interaction, pharmacokinetic studies, and broader drug-drug interaction research. This guide pairs practical solubilization and workflow controls with a CYP3A-independent comparator concept derived from the dabigatran reference study.

• Vemurafenib (PLX4032) in Melanoma Research

  2026-09-30

  Build genotype-aware melanoma assays with Vemurafenib (PLX4032), from short-term MAPK pathway measurements to resistance modeling and xenograft studies. This workflow emphasizes solvent control, matched BRAF backgrounds, early signaling kinetics, and ARID1A-linked resistance biology.

• Trichostatin A (TSA): HDAC Workflow Guide

  2026-09-29

  Trichostatin A (TSA) provides reversible HDAC inhibition for probing histone acetylation, cell-cycle control, differentiation, and cancer-cell responses. This guide translates TSA into practical dose-response, viability, and oncolytic-virus combination workflows while emphasizing controls, solvent management, and assay-specific optimization.

• Sulfamonomethoxine in Aquatic Research

  2026-09-29

  Sulfamonomethoxine, or SMM, requires different interpretation in antibacterial, antiprotozoal, and environmental assays. This evidence-based guide connects DHPS inhibition, the Azumiobodo hoyamushi study, formulation constraints, and aquatic risk assessment to improve experimental decisions.

• Toremifene in Breast Cancer: 20 Years of Evidence

  2026-09-28

  This review evaluates two decades of clinical and pharmacologic evidence for toremifene, a selective estrogen receptor modulator used in hormone-sensitive breast cancer. Its central contribution is to place toremifene alongside tamoxifen and aromatase inhibitors while examining efficacy, safety, metabolism, CYP2D6, and patient-specific endocrine treatment decisions.

• Stress Fiber Anisotropy and Force-Mode Gene Control

  2026-09-28

  Wei and colleagues used three-dimensional magnetic twisting cytometry to compare how force direction affects cell stiffness, chromatin deformation, and DHFR transcription. Their results identify stress-fiber anisotropy as a mechanical factor that helps explain why force modes can produce different cellular responses, while also showing that stiffness alone does not predict the transcriptional outcome.

• Oteseconazole (VT-1161): Assay Workflows & DDI Context

  2026-09-27

  A practical guide to using Oteseconazole (VT-1161) in Candida susceptibility studies, from stock preparation to MIC interpretation. It also explains why antifungal potency and drug-interaction screening belong in separate, complementary assay tracks.

• Escitalopram Workflows for Anxiety and SERT Research

  2026-09-26

  Build serotonin-transporter experiments around Escitalopram’s nanomolar activity while keeping assay context and vehicle controls explicit. A clinical moderator analysis offers a useful lesson for anxiolytic activity studies: measure anxiety-related outcomes separately rather than assuming they track depression endpoints.

• Mutational Landscapes in Multiple Myeloma Cell Lines

  2026-09-25

  This 2019 study used whole-exome sequencing across a diverse panel of human multiple myeloma cell lines to map protein-altering mutations, affected pathways, and associations with drug sensitivity. Its main contribution is a molecular resource for choosing and interpreting cell-line models; the reported mutation–response relationships are hypothesis-generating, not proof of causation or clinical response.

• Dronedarone (Multaq): Beyond the Product Profile

  2026-09-25

  A translational perspective on using Dronedarone (Multaq) in atrial fibrillation and atrial flutter research. We connect KCa2 channel evidence to practical assay design, highlight what the data do—and do not—support, and outline how to position this research compound in cardiac arrhythmia pharmacology workflows.

• Rapamycin (Sirolimus) for Autophagy Research

  2026-09-24

  Use Rapamycin (Sirolimus) as a controlled mTOR perturbation to test how growth signaling intersects with autophagy, survival, and viral latency in cancer models. A practical dose-and-time workflow helps separate target engagement from downstream effects—and avoids assuming rapamycin was tested in the featured EBV study.

• FPH1 (BRD-6125) for Functional Hepatocyte Workflows

  2026-09-24

  FPH1 (BRD-6125) supports workflows that pair hepatocyte expansion with functional readouts, including albumin secretion, CYP3A4, and AFP. This guide shows how to build a controlled proliferation assay and how to interpret a separate light-regulated gene therapy study without confusing its findings with evidence for FPH1.

• FPH1 (BRD-6125): Designing Functional Hepatocyte Assays

  2026-09-23

  FPH1 (BRD-6125) can support hepatocyte expansion, but cell growth alone does not establish a useful liver model. This guide explains how to pair proliferation measurements with functional readouts and interpret results alongside emerging light-regulated gene-expression research.

8104 records 1/541 page Next 12345 下5页 Last page